Travel broadens the mind, but it also, rather less poetically, can disrupt the gut. For the health and nutrition industry, that disruption highlights a genuine and underserved formulation opportunity.
Travellers’ diarrhoea (TD) remains one of the most common medical complaints among people travelling internationally. Estimates suggest it affects up to 70% of travellers and is particularly acute for higher-risk destinations across Asia, Africa, Latin America and the Middle East.
Beyond TD itself, a broader range of digestive discomforts, such as bloating, irregular bowel habits, and abdominal pain, are frequently reported by travellers, even those who avoid overt illness. The gut microbiome lies at the heart of much of this disruption, and it is here that formulators should be paying close attention.
Why travel can disrupt the gut
The gut microbiome is a remarkably responsive ecosystem. It is influenced by a number of different factors, including diet, sleep, stress, circadian rhythm and microbial exposure. All of these factors can be disrupted by travel. For example, time zone shifts alter the timing of gut motility, while changed dietary patterns, including richer or less familiar foods, modify fermentation dynamics in the colon. Similarly, sleep deprivation activates stress pathways that can influence intestinal permeability, and exposure to novel microbial environments through local water sources, different food-handling practices and equally different pathogens, challenges the gut microbiome’s capacity to maintain its defensive integrity.
The result of this is a gut that is, at least temporarily, less resilient. Beneficial bacterial populations, particularly bifidobacteria, can decline under these combined pressures, reducing the competitive exclusion of pathogens and potentially weakening the intestinal immune response. The clinical consequences can range from mild discomfort to clinically significant diarrhoeal episodes and severe dehydration, with real quality-of-life impacts.
The clinical evidence: Bimuno® GOS and travellers’ diarrhoea
Two robust double-blind, placebo-controlled human studies have investigated the potential of Bimuno GOS, our galactooligosaccharide (GOS) prebiotic ingredient, to support digestive and immune resilience during travel.
Drakoularakou et al. (2010) enrolled healthy volunteers travelling to destinations of low or high TD risk for a minimum of two weeks, with 159 subjects completing the study. Participants consumed either Bimuno GOS or a placebo daily, beginning one week before departure.
Those in the Bimuno GOS group demonstrated a significantly lower incidence and reduced duration of diarrhoea, by approximately 15% and 2 days respectively, as well as reduced duration of associated abdominal pain, compared with the placebo group. Quality of life scores, assessed using a validated World Health Organization questionnaire, were significantly higher among those in the Bimuno GOS group that experienced diarrhoea.
The second study, Hasle et al. (2017), conducted at the Oslo Travel Clinic, extended this work with a larger cohort travelling to a diverse range of destinations for 7–15 days. Among those subjects (334) who adhered fully to the daily dosing regimen (or only missed one day), Bimuno GOS was associated with a significant reduction in diarrhoea incidence compared to the placebo. Notably, the effect was most pronounced for self-limiting, one-day diarrhoeal episodes and became statistically significant from day eight of supplementation onwards. This is consistent with the time required for meaningful shifts in gut microbiome composition to take effect. The authors noted that starting supplementation at least one week before departure appears important for achieving this benefit.
Across both studies, tolerability of Bimuno GOS was strong, with adverse effects no greater than the placebo.
Turning potential into opportunity
These findings open a clearly defined category for product developers. Travel health is an established product segment, but it has historically been dominated by rehydration solutions and antibiotic-adjacent positioning.
The evidence around prebiotic GOS offers something meaningfully different: a microbiome-targeted approach that works upstream of illness, building digestive resilience and supporting the immune system rather than responding once disruption takes hold.
The fast action of Bimuno GOS’s effects also has direct relevance for dosage form and format strategy. Products designed to be taken before and during travel, fit naturally into daily supplement routines, capsules, functional beverages, or travel-friendly stick pack formats. The ingredient’s established stability profile and low effective dose support a range of delivery systems without significant formulation challenge.
Beyond TD specifically, the broader microbiome disruption that travel causes creates legitimate positioning around general digestive comfort, including bloating, irregular transit and abdominal discomfort, all of which have consumer attention.
The science is there and the market need is real. For formulators looking to bring genuine clinical evidence into the travel health nutrition space, Bimuno GOS represents a compelling, scientifically supported starting point.
Frequently Asked Questions
What is travellers’ diarrhoea?
Travellers’ diarrhoea is a gastrointestinal condition typically defined as three or more loose or watery stools per day occurring during or shortly after travel, which is accompanied by at least one other gastrointestinal symptom such as abdominal cramps, nausea or vomiting, or fever.
Can prebiotics help with travellers’ diarrhoea?
Clinical evidence indicates that supplementation with prebiotic Bimuno GOS, a proprietary mix of galactooligosaccharides (GOS), can significantly reduce the incidence and duration of travellers’ diarrhoea in healthy adults when taken daily from at least one week before departure.
How does the gut microbiome affect digestive health during travel?
Travel disrupts multiple factors that shape the gut microbiome, including diet, sleep, circadian rhythm and microbial exposure. These factors can reduce populations of beneficial gut bacteria and lower the gut’s natural resilience against pathogens.
What is a galactooligosaccharide (GOS)?
A galactooligosaccharide is a type of non-digestible prebiotic fibre that selectively nourishes beneficial gut bacteria, particularly bifidobacteria, supporting a balanced gut microbiome.
How long before travel should you start taking a prebiotic?
Based on clinical study findings with Bimuno GOS, supplementation should ideally begin at least seven or eight days before departure to allow sufficient time for meaningful shifts in gut microbiome composition to take effect.
What digestive issues are common during travel?
Alongside travellers’ diarrhoea, common travel-related digestive complaints include bloating, abdominal discomfort, altered bowel habits and irregular transit, all of which are linked to microbiome disruption caused by changes in diet, routine and microbial environment.
What formats can a prebiotic GOS ingredient be incorporated into?
Bimuno GOS is suitable for a range of delivery formats including sachets, capsules, functional beverages and stick packs, with a low effective daily dose and high stability making it easy to work with.
